{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:29:58Z","timestamp":1792524598393,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["22B06"],"award-info":[{"award-number":["22B06"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40291-026-00865-2","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:12:33Z","timestamp":1783365153000},"page":"821-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multiplex RT-PCR-Based Sequencing Assay to Detect Kidney Cancer-Specific Splice Variants in Tumor Tissues and Plasma Cell-Free RNAs"],"prefix":"10.1007","volume":"30","author":[{"given":"Kapil K.","family":"Avasthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendrick H.","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngchul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola M. Ramos","family":"Echevarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz M.","family":"Darst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly P.","family":"Zea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell T.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Vosoughi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9364-8572","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"3","key":"865_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","volume":"11","author":"SA Padala","year":"2020","unstructured":"Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79\u201387.","journal-title":"World J Oncol."},{"issue":"1","key":"865_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"865_CR3","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.7150\/jca.105713","volume":"16","author":"S Zou","year":"2025","unstructured":"Zou S, Cui L, Pai P, et al. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis. J Cancer. 2025;16(5):1591\u20137.","journal-title":"J Cancer"},{"issue":"6","key":"865_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32060359","volume":"32","author":"B Millan","year":"2025","unstructured":"Millan B, Loebach L, Blachman-Braun R, et al. Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance. Curr Oncol. 2025;32(6):359.","journal-title":"Curr Oncol"},{"issue":"6","key":"865_CR5","volume":"7","author":"J Deng","year":"2024","unstructured":"Deng J, Tu S, Li L, et al. Diagnostic, predictive and prognostic molecular biomarkers in clear cell renal cell carcinoma: A retrospective study. Cancer Rep (Hoboken). 2024;7(6):e2116.","journal-title":"Cancer Rep (Hoboken)."},{"issue":"4","key":"865_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/1078-0432.CCR-23-1892","volume":"30","author":"I Lyskjaer","year":"2024","unstructured":"Lyskj\u00e6r I, Iisager L, Axelsen CT, et al. Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic. Clin Cancer Res. 2024;30(4):663\u201372.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"865_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-021-00486-7","volume":"6","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Qian J, Gu C, et al. Alternative splicing and cancer: a systematic review. Signal Transduct Target Ther. 2021;6(1):78.","journal-title":"Signal Transduct Target Ther"},{"issue":"D1","key":"865_CR8","doi-asserted-by":"publisher","first-page":"D1196","DOI":"10.1093\/nar\/gkac955","volume":"51","author":"S Wu","year":"2023","unstructured":"Wu S, Huang Y, Zhang M, et al. ASCancer Atlas: a comprehensive knowledgebase of alternative splicing in human cancers. Nucleic Acids Res. 2023;51(D1):D1196\u2013204.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"865_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","volume":"23","author":"RK Bradley","year":"2023","unstructured":"Bradley RK, Anczukow O. RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer. 2023;23(3):135\u201355.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"865_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1476","volume":"9","author":"LM Urbanski","year":"2018","unstructured":"Urbanski LM, Leclair N, Anczuk\u00f3w O. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley Interdiscip Rev RNA. 2018;9(4):e1476.","journal-title":"Wiley Interdiscip Rev RNA."},{"key":"865_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.868664","volume":"12","author":"AJ Murphy","year":"2022","unstructured":"Murphy AJ, Li AH, Li P, et al. Therapeutic Targeting of Alternative Splicing: A New Frontier in Cancer Treatment. Front Oncol. 2022;12:868664.","journal-title":"Front Oncol"},{"issue":"4","key":"865_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.eururo.2022.05.021","volume":"82","author":"A Chang","year":"2022","unstructured":"Chang A, Chakiryan NH, Du D, et al. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. Eur Urol. 2022;82(4):354\u201362.","journal-title":"Eur Urol"},{"issue":"2","key":"865_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.euf.2019.12.001","volume":"7","author":"S Zaman","year":"2021","unstructured":"Zaman S, Hajiran A, Coba GA, et al. Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. Eur Urol Focus. 2021;7(2):373\u201380.","journal-title":"Eur Urol Focus"},{"issue":"5","key":"865_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2024.102041","volume":"104","author":"T Peak","year":"2024","unstructured":"Peak T, Tian Y, Patel A, et al. Pathogenic Roles for RNASET2 in Clear Cell Renal Cell Carcinoma. Lab Invest. 2024;104(5):102041.","journal-title":"Lab Invest"},{"key":"865_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1472-6750-11-80","volume":"11","author":"JR Dobosy","year":"2011","unstructured":"Dobosy JR, Rose SD, Beltz KR, et al. RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers. BMC Biotechnol. 2011;11:80.","journal-title":"BMC Biotechnol"},{"issue":"1","key":"865_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40364-022-00409-w","volume":"10","author":"L Cabus","year":"2022","unstructured":"Cab\u00fas L, Lagarde J, Curado J, et al. Current challenges and best practices for cell-free long RNA biomarker discovery. Biomark Res. 2022;10(1):62.","journal-title":"Biomark Res."},{"issue":"8","key":"865_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0308711","volume":"19","author":"EJ Northrop-Albrecht","year":"2024","unstructured":"Northrop-Albrecht EJ, Wu CW, Berger CK, et al. An investigation of plasma cell-free RNA for the detection of colorectal cancer: From transcriptome marker selection to targeted validation. PLoS One. 2024;19(8):e0308711.","journal-title":"PLoS ONE"},{"issue":"1","key":"865_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s43856-026-01507-8","volume":"6","author":"A Morlion","year":"2026","unstructured":"Morlion A, Decruyenaere P, Schoofs K, et al. Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls. Commun Med (Lond). 2026;6(1):230.","journal-title":"Commun Med (Lond)."},{"issue":"8063","key":"865_CR19","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41586-025-08834-1","volume":"641","author":"MC Nesselbush","year":"2025","unstructured":"Nesselbush MC, Luca BA, Jeon YJ, et al. An ultrasensitive method for detection of cell-free RNA. Nature. 2025;641(8063):759\u201368.","journal-title":"Nature"},{"issue":"9","key":"865_CR20","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.tips.2025.08.001","volume":"46","author":"JCM Wan","year":"2025","unstructured":"Wan JCM, Eldarwi A, Diaz LA Jr. RARE-seq: an inflection point in cfRNA liquid biopsy. Trends Pharmacol Sci. 2025;46(9):823\u20135.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"865_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev-cancerbio-030617-050407","volume":"3","author":"L Escobar-Hoyos","year":"2019","unstructured":"Escobar-Hoyos L, Knorr K, Abdel-Wahab O. Aberrant RNA splicing in cancer. Annu Rev Cancer Biol. 2019;3(1):167\u201385.","journal-title":"Annu Rev Cancer Biol."},{"issue":"6","key":"865_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/biom15060789","volume":"15","author":"H Chen","year":"2025","unstructured":"Chen H, Tang J, Xiang J. Alternative splicing in tumorigenesis and cancer therapy. Biomolecules. 2025;15(6):789.","journal-title":"Biomolecules"},{"issue":"2","key":"865_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","volume":"34","author":"A Kahles","year":"2018","unstructured":"Kahles A, Lehmann KV, Toussaint NC, et al. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell. 2018;34(2):211\u2013224.e6.","journal-title":"Cancer Cell"},{"issue":"1","key":"865_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","volume":"29","author":"AA Hakimi","year":"2016","unstructured":"Hakimi AA, Reznik E, Lee CH, et al. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell. 2016;29(1):104\u201316.","journal-title":"Cancer Cell"},{"issue":"1","key":"865_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01616-9","volume":"39","author":"AR Farina","year":"2020","unstructured":"Farina AR, Cappabianca L, Sebastiano M, et al. Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer. J Exp Clin Cancer Res. 2020;39(1):110.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"865_CR26","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1101\/gr.279345.124","volume":"35","author":"T Karakulak","year":"2025","unstructured":"Karakulak T, Zajac N, Bolck HA, et al. Heterogeneous and novel transcript expression in single cells of patient-derived clear cell renal cell carcinoma organoids. Genome Res. 2025;35(4):698\u2013711.","journal-title":"Genome Res"},{"issue":"5","key":"865_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16261","volume":"9","author":"M Albitar","year":"2023","unstructured":"Albitar M, Zhang H, Charifa A, et al. Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors. Heliyon. 2023;9(5):e16261.","journal-title":"Heliyon."},{"issue":"8","key":"865_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41571-020-0350-x","volume":"17","author":"SC Bonnal","year":"2020","unstructured":"Bonnal SC, Lopez-Oreja I, Valcarcel J. Roles and mechanisms of alternative splicing in cancer: implications for care. Nat Rev Clin Oncol. 2020;17(8):457\u201374.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"865_CR29","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.37349\/etat.2024.00271","volume":"5","author":"L Omri","year":"2024","unstructured":"Omri L, Naigeon M, Flippot R, et al. Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma. Explor Target Antitumor Ther. 2024;5(6):1199\u2013222.","journal-title":"Explor Target Anti-tumor Ther"},{"issue":"11","key":"865_CR30","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3390\/genes14112020","volume":"14","author":"MR Islam","year":"2023","unstructured":"Islam MR, Nagar P, Neetole ST, et al. RNA Splicing in Cancer and Targeted Therapies. Genes (Basel). 2023;14(11):2020.","journal-title":"Genes (Basel)."},{"issue":"1","key":"865_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13046-025-03279-w","volume":"44","author":"X Lv","year":"2025","unstructured":"Lv X, Sun X, Gao Y, et al. Targeting RNA splicing modulation: new perspectives for anticancer strategy?. J Exp Clin Cancer Res. 2025;44(1):32.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"865_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"865_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71\u201388.","journal-title":"Nat Rev Genet"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00865-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00865-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00865-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:31:53Z","timestamp":1787380313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00865-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["865"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00865-2","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by the Florida Department of Health (22B06 to BJM and LW). The research was facilitated by the Total Cancer Care Protocol and the Tissue Core, and Genomic Core Shared Resource at the H. Lee Moffitt Cancer Center & Research Institute, a National Cancer Institute-designated Comprehensive Cancer Center (P30-CA076292).","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kapil K. Avasthi, Kendrick H. Yim, Youngchul Kim, Paola M. Ramos Echevarria, Liz M. Darst, Nicholas Abreu, Kelly P. Zea, Mitchell T. Hayes, Aram Vosoughi, Brandon J. Manley, and Liang Wang have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of the H. Lee Moffitt Cancer Center and Research Institute under the Total Cancer Care protocol (MCC#14690; Advarra IRB Pro00014441).","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data on patient age, sex, clinical test results, and pathological features were extracted from the patients\u2019 medical records. All participants provided written informed consent for molecular characterization of their tissues and blood samples in accordance with the Total Cancer Care protocol.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data produced in the present study will be shared upon completion of the institutional data transfer agreement.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KKA, BJM, and LW conceived and designed the study. KKA, BJM, and LW acquired, analyzed, and interpreted the data. BJM and LW provided essential research tools, and PMRE and LMD assisted with sample collection. KKA, BJM, and LW drafted the manuscript. KKA, KHY, YK, NB, KPZ, MTH, AV, BJM, and LW critically reviewed and revised the manuscript. All authors read and approved the final version.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}